Key result
Adding dexmedetomidine to midazolam and propofol is linked to ~2% lower mortality and shorter hospital stays.
Why the study?
Does the addition of dexmedetomidine to midazolam and propofol improve clinical and economic outcomes in patients after cardiac surgery?
Population
10,352 patients after cardiac valve or vessel surgery from a nationally representative sample of 250 medical…
Comparison
Dexmedetomidine added to midazolam and propofol vs Midazolam plus propofol
Design
Cohort
Follow-up
Inpatient stay
Authors
Loading...
Should not yet change post-cardiac surgery sedation; leaves open causal benefits pending randomized confirmation.
Cohort (n=10,352)
Yes
Does the addition of dexmedetomidine to midazolam and propofol improve clinical and economic outcomes in patients after cardiac surgery?
Effect estimate: 2% reduction in mortality
Absolute Risk Reduction: 2%
p-value: p=0.0142
The addition of dexmedetomidine to standard sedation with midazolam and propofol after cardiac surgery may be associated with reduced hospital length of stay, ICU time, mortality, and overall costs, though baseline confounding limits causal inference.
Dasta et al. (2006) conducted a cohort in Cardiac valve or vessel surgery (n=10,352). Dexmedetomidine, midazolam, and propofol vs. Midazolam and propofol was evaluated on Total charges, hospital length of stay, ICU/CCU days, and mortality (2% reduction in mortality, p=0.0142). Addition of dexmedetomidine to midazolam and propofol after cardiac surgery was associated with significant reductions in total charges, length of stay, ICU days, and mortality (2% reduction, P=0.0142).
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: